Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Readi-Cat 2

×

Overview

What is Readi-Cat 2?

READI-CAT 2 and READI-CAT 2 SMOOTHIE (barium sulfate) are radiographic contrast agents supplied as a suspension (2% w/v) for oral administration. The active ingredient barium sulfate is designated chemically as BaSO with a molecular weight of 233.4 g/mol, a density of 4.5 g/cm, and the following chemical structure:

READI-CAT 2 products contain excipients including: benzoic acid, citric acid, potassium sorbate, saccharin sodium, simethicone emulsion, sodium benzoate, sodium citrate, sorbitol solution, xanthan gum, and purified water.

READI-CAT 2 products also contain natural and artificial flavorings including: banana, blueberry, orange, vanilla, chocolate, and coffee flavors.



What does Readi-Cat 2 look like?



What are the available doses of Readi-Cat 2?

Oral suspension: 9 grams of barium sulfate supplied as a suspension (2% w/v) in a single-dose HDPE plastic bottle.

What should I talk to my health care provider before I take Readi-Cat 2?

How should I use Readi-Cat 2?

READI-CAT 2 and READI-CAT 2 SMOOTHIES are indicated for use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.

Base dosing on individual needs and procedure to be performed.


What interacts with Readi-Cat 2?

Sorry No Records found


What are the warnings of Readi-Cat 2?

Sorry No Records found


What are the precautions of Readi-Cat 2?

Sorry No Records found


What are the side effects of Readi-Cat 2?

Sorry No records found


What should I look out for while using Readi-Cat 2?

READI-CAT 2 products are contraindicated in patients:


What might happen if I take too much Readi-Cat 2?

Sorry No Records found


How should I store and handle Readi-Cat 2?

16.1 How SuppliedREADI-CAT 2 and READI-CAT 2 SMOOTHIES (barium sulfate) are supplied as suspensions (2 % w/v) in a unit dose in a single-dose HDPE plastic bottle containing 9 grams of barium sulfate in 450 mL.READI-CAT 2 products are provided in the following flavors as:READI-CAT 2: (Orange): 24 x 450 mL bottles (NDC 32909-724-03)READI-CAT 2 SMOOTHIE (Banana): 24 x 450 mL bottles (NDC 32909-722-03)READI-CAT 2 SMOOTHIE (Berry): 24 x 450 mL bottles (NDC 32909-711-03)READI-CAT 2 SMOOTHIE (Creamy Vanilla): 24 x 450 mL bottles (NDC 32909-756-03)READI-CAT 2 SMOOTHIE (Mochaccino): 24 x 450 mL bottles (NDC 32909-777-03)16.2 Storage and HandlingStore at USP controlled room temperature, 20 to 25°C (68 to 77° F)16.1 How SuppliedREADI-CAT 2 and READI-CAT 2 SMOOTHIES (barium sulfate) are supplied as suspensions (2 % w/v) in a unit dose in a single-dose HDPE plastic bottle containing 9 grams of barium sulfate in 450 mL.READI-CAT 2 products are provided in the following flavors as:READI-CAT 2: (Orange): 24 x 450 mL bottles (NDC 32909-724-03)READI-CAT 2 SMOOTHIE (Banana): 24 x 450 mL bottles (NDC 32909-722-03)READI-CAT 2 SMOOTHIE (Berry): 24 x 450 mL bottles (NDC 32909-711-03)READI-CAT 2 SMOOTHIE (Creamy Vanilla): 24 x 450 mL bottles (NDC 32909-756-03)READI-CAT 2 SMOOTHIE (Mochaccino): 24 x 450 mL bottles (NDC 32909-777-03)16.2 Storage and HandlingStore at USP controlled room temperature, 20 to 25°C (68 to 77° F)16.1 How SuppliedREADI-CAT 2 and READI-CAT 2 SMOOTHIES (barium sulfate) are supplied as suspensions (2 % w/v) in a unit dose in a single-dose HDPE plastic bottle containing 9 grams of barium sulfate in 450 mL.READI-CAT 2 products are provided in the following flavors as:READI-CAT 2: (Orange): 24 x 450 mL bottles (NDC 32909-724-03)READI-CAT 2 SMOOTHIE (Banana): 24 x 450 mL bottles (NDC 32909-722-03)READI-CAT 2 SMOOTHIE (Berry): 24 x 450 mL bottles (NDC 32909-711-03)READI-CAT 2 SMOOTHIE (Creamy Vanilla): 24 x 450 mL bottles (NDC 32909-756-03)READI-CAT 2 SMOOTHIE (Mochaccino): 24 x 450 mL bottles (NDC 32909-777-03)16.2 Storage and HandlingStore at USP controlled room temperature, 20 to 25°C (68 to 77° F)16.1 How SuppliedREADI-CAT 2 and READI-CAT 2 SMOOTHIES (barium sulfate) are supplied as suspensions (2 % w/v) in a unit dose in a single-dose HDPE plastic bottle containing 9 grams of barium sulfate in 450 mL.READI-CAT 2 products are provided in the following flavors as:READI-CAT 2: (Orange): 24 x 450 mL bottles (NDC 32909-724-03)READI-CAT 2 SMOOTHIE (Banana): 24 x 450 mL bottles (NDC 32909-722-03)READI-CAT 2 SMOOTHIE (Berry): 24 x 450 mL bottles (NDC 32909-711-03)READI-CAT 2 SMOOTHIE (Creamy Vanilla): 24 x 450 mL bottles (NDC 32909-756-03)READI-CAT 2 SMOOTHIE (Mochaccino): 24 x 450 mL bottles (NDC 32909-777-03)16.2 Storage and HandlingStore at USP controlled room temperature, 20 to 25°C (68 to 77° F)16.1 How SuppliedREADI-CAT 2 and READI-CAT 2 SMOOTHIES (barium sulfate) are supplied as suspensions (2 % w/v) in a unit dose in a single-dose HDPE plastic bottle containing 9 grams of barium sulfate in 450 mL.READI-CAT 2 products are provided in the following flavors as:READI-CAT 2: (Orange): 24 x 450 mL bottles (NDC 32909-724-03)READI-CAT 2 SMOOTHIE (Banana): 24 x 450 mL bottles (NDC 32909-722-03)READI-CAT 2 SMOOTHIE (Berry): 24 x 450 mL bottles (NDC 32909-711-03)READI-CAT 2 SMOOTHIE (Creamy Vanilla): 24 x 450 mL bottles (NDC 32909-756-03)READI-CAT 2 SMOOTHIE (Mochaccino): 24 x 450 mL bottles (NDC 32909-777-03)16.2 Storage and HandlingStore at USP controlled room temperature, 20 to 25°C (68 to 77° F)16.1 How SuppliedREADI-CAT 2 and READI-CAT 2 SMOOTHIES (barium sulfate) are supplied as suspensions (2 % w/v) in a unit dose in a single-dose HDPE plastic bottle containing 9 grams of barium sulfate in 450 mL.READI-CAT 2 products are provided in the following flavors as:READI-CAT 2: (Orange): 24 x 450 mL bottles (NDC 32909-724-03)READI-CAT 2 SMOOTHIE (Banana): 24 x 450 mL bottles (NDC 32909-722-03)READI-CAT 2 SMOOTHIE (Berry): 24 x 450 mL bottles (NDC 32909-711-03)READI-CAT 2 SMOOTHIE (Creamy Vanilla): 24 x 450 mL bottles (NDC 32909-756-03)READI-CAT 2 SMOOTHIE (Mochaccino): 24 x 450 mL bottles (NDC 32909-777-03)16.2 Storage and HandlingStore at USP controlled room temperature, 20 to 25°C (68 to 77° F)


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Due to its high atomic number, barium (the active ingredient in READI-CAT 2 products) is opaque to x-rays and therefore acts as a positive contrast agent for radiographic studies.

Non-Clinical Toxicology
READI-CAT 2 products are contraindicated in patients:

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, quinolones and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control. binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide was reported in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).

In studies assessing the effect of colesevelam on the pharmacokinetics of glipizide ER in healthy volunteers, reductions in glipizide AUC and C of 12% and 13%, respectively were observed when colesevelam was coadministered with glipizide ER. When glipizide ER was administered 4 hours prior to colesevelam, there was no significant change in glipizide AUC or C , -4% and 0%, respectively. Therefore, glipizide should be administered at least 4 hours prior to colesevelam to ensure that colesevelam does not reduce the absorption of glipizide.

Barium sulfate preparations contain a number of excipients, including natural and artificial flavors and may induce serious hypersensitivity reactions. The manifestations include hypotension, bronchospasm and other respiratory impairments, dermal reactions including rashes, urticaria, and itching. A history of bronchial asthma, atopy, or a previous reaction to a contrast agent may increase the risk for hypersensitivity reactions. Emergency equipment and trained personnel should be immediately available for treatment of a hypersensitivity reaction.

The following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).